Skip to main content
Article thumbnail
Location of Repository

Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy

By Harout K Tossonian, Jesse D Raffa, Jason Grebely, Mark Viljoen, Annabel Mead, Milan Khara, Mark McLean, Ashok Krishnamurthy, Stanley DeVlaming and Brian Conway


To evaluate the impact of mutations at reverse transcriptase codon 135 on treatment outcomes in patients receiving NNRTI-based antiretroviral therapy, a total of 68 patients (30 with and 38 without baseline mutations at codon 135) were evaluated. Median increases in CD4 counts were 135 and 90 cells/mm3 (p=0.32), virologic suppression (HIV RNA < 400 copies/mL) was achieved in 16 (53%) and 16 (42%) patients (p=0.50), while NNRTI resistance was detected in 10/14 (71%) and 16/22 (73%) in patients with and without mutations at codon 135, respectively. Patients who experienced a virologic breakthrough and had a baseline mutation at codon 135 were more likely to evolve a single NNRTI resistance mutation (8/14 vs 4/22, p=0.029) but less likely to evolve multiple NNRTI resistance mutations (2/14 vs 12/22, p = 0.033). Mutations at codon 135 do not affect response rates, but affect the pattern of development of NNRTI resistance mutations. This has important implications for the subsequent use of newer NNRTIs such as etravirine in salvage therapy

Topics: Article
Publisher: Bentham Science Publishers Ltd.
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2000). A novel phenotypic drug susceptibility assay for HIV type 1. J Antimicrob Chemother
    2. (2005). A systematic approach to the treatment of HIV and hepatitis C virus infection in the inner city: a Canadian perspective. Clin Infect Dis
    3. (1993). Crystal structure of human immunodecifiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.
    4. (2004). Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis
    5. (2003). High-level resistance to HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the absence of known resistance mutations:
    6. (2003). Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. Antivir Ther
    7. (2004). Mutations at codon 135 at baseline are associated with the accumulation of NNRTI-resistance mutations while on EFV-containing regimens:
    8. (2006). Prevalence and impact of primary resistance in drug naïve injection drug users (IDUs).
    9. (1999). Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA
    10. (2000). Reduced susceptibility of human immunodeficiency virus type I (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites.
    11. Role of the 7-8-loop in the 51 kDa subunit of HIV-1 reverse
    12. (2003). The impact of non-B subtype HIV-1 infection on antiretroviral drug susceptibility in North and South America:
    13. (2004). The prevalence of antiretroviral drug resistance in the United States. AIDS
    14. (2006). Update of the drug resistance mutations in HIV-1: Fall
    15. (2004). Which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.